Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Completed · Phase 3 · Has a placebo group

Conditions studied: Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.

Key facts

Study ID
NCT00489411
Run by
Alliance for Clinical Trials in Oncology
People needed
231
Starts
2008-04-01
Expected to finish
2013-03-01
Last updated by the study team
2017-04-26

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.